KRAS mutations are among the most critical biomarkers in oncology, strongly linked with tumour development, resistance to targeted therapies, and poor prognosis. Found in approximately 20–50% of colorectal cancers and 15–30% of lung cancers, mutations in the KRAS gene — especially in codons 12 and 13 of exon 2 — render standard anti-EGFR therapies ineffective, making rapid and accurate KRAS mutation detection essential for guiding personalised treatment strategies. KRAS mutation detection is a standard recommendation in NCCN guidelines for metastatic colorectal cancer, underscoring its importance in identifying patients who may not benefit from EGFR-targeted drugs.
To address this critical clinical need, Genes2Me introduces the KRAS-Q Real-Time PCR Kit — an advanced in vitro diagnostic solution designed for highly sensitive and specific detection of KRAS somatic mutations in DNA extracted from fresh, frozen, or FFPE tissue samples. With a limit of detection as low as 1% mutation frequency, the kit empowers clinicians to make confident, evidence-based treatment decisions.
The KRAS-Q Kit utilises a wild-type blocking technique combined with allele-specific amplification to selectively detect eight clinically significant KRAS mutations of exon 2, including Gly12Asp, Gly12Val, and Gly13Asp. Detection is achieved via fluorescent TaqMan probes (FAM reporter, BHQ2 quencher), ensuring robust and reliable results. An integrated internal control validates DNA quality, reagent performance, and overall assay integrity in every run, minimising the risk of false-negative results and ensuring dependable performance across challenging sample types including FFPE.
KRAS mutation testing is a cornerstone of precision oncology in colorectal and lung cancer management. Accurate identification of mutation-positive patients enables clinicians to avoid ineffective anti-EGFR therapies and instead select targeted treatment regimens that align with the individual tumour's genetic profile. With 100% analytical sensitivity and specificity, clinical sensitivity and specificity of 99%, and a limit of detection of 1% mutation frequency, the KRAS-Q Kit provides laboratories with dependable molecular diagnostic performance for personalised oncology treatment planning.
Detects eight key KRAS exon 2 mutations at codons 12 and 13, including Gly12Asp, Gly12Val, and Gly13Asp.
100% analytical sensitivity and specificity, clinical sensitivity and specificity of 99%, and precision with CV less than 3%.
Wild-type blocking combined with allele-specific amplification and TaqMan probe chemistry (FAM reporter, BHQ2 quencher) ensures selective and reliable mutation detection.
Validates DNA quality, reagent integrity, and assay performance in every run, minimising false-negative results.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Robust detection across fresh tissue, frozen samples, and challenging FFPE specimens for routine clinical use.
With the KRAS-Q Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful detection of KRAS somatic mutations. By supporting rapid identification of mutation-positive patients, personalised oncology treatment planning, and avoidance of ineffective therapies, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the KRAS-Q Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
When the Ct value of the sample to be tested is outside the reference range and there is a typical S-shaped amplification curve, the test result is positive; When the Ct value of the sample to be tested is within the reference range, or the Ct value is outside the reference range but there is no typical S-shaped amplification curve, the test result is negative.
Channel 1 Slope: -3.392 Intercept: 39.372 Correlation: -0.998 Efficiency 3: 97.1430 Channel 3 Slope: -3.240 Intercept: 38.672 Correlation: -0.999 Efficiency 2: 103.52
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| KRAS-Q Real-Time PCR Kit | G610052-1 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
